RIGL Quote, Financials, Valuation and Earnings

Catalyst Pharmaceuticals, Inc. has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of 35.57%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48%.

Rigel Pharmaceuticals, Inc. has a consensus price target of $51.60, signalling upside risk potential of 51.1%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.57 which suggests that it could grow by 41.45%. Given that Rigel Pharmaceuticals, Inc. has higher upside potential than Catalyst Pharmaceuticals, Inc., analysts believe Rigel Pharmaceuticals, Inc. is more attractive than Catalyst Pharmaceuticals, Inc..

Rigel Pharmaceuticals, Inc. has a beta of 1.111, which suggesting that the stock is 11.137% more volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.735, suggesting its less volatile than the S&P 500 by 26.455%.

Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are smaller than Catalyst Pharmaceuticals, Inc. quarterly revenues of $148.4M. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is lower than Catalyst Pharmaceuticals, Inc.'s net income of $52.8M. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 5.54x while Catalyst Pharmaceuticals, Inc.'s PE ratio is 14.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 2.22x versus 5.37x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics, Inc. has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of 10.24%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

Rigel Pharmaceuticals, Inc. has a consensus price target of $51.60, signalling upside risk potential of 51.1%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.4%. Given that Rigel Pharmaceuticals, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Rigel Pharmaceuticals, Inc. is more attractive than Amicus Therapeutics, Inc..

Rigel Pharmaceuticals, Inc. has a beta of 1.111, which suggesting that the stock is 11.137% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.857%.

Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is higher than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 5.54x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 2.22x versus 7.32x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ironwood Pharmaceuticals, Inc. has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of 32.84%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat Ironwood Pharmaceuticals, Inc.'s return on equity of --.

Rigel Pharmaceuticals, Inc. has a consensus price target of $51.60, signalling upside risk potential of 51.1%. On the other hand Ironwood Pharmaceuticals, Inc. has an analysts' consensus of $3.17 which suggests that it could fall by -30.56%. Given that Rigel Pharmaceuticals, Inc. has higher upside potential than Ironwood Pharmaceuticals, Inc., analysts believe Rigel Pharmaceuticals, Inc. is more attractive than Ironwood Pharmaceuticals, Inc..

Rigel Pharmaceuticals, Inc. has a beta of 1.111, which suggesting that the stock is 11.137% more volatile than S&P 500. In comparison Ironwood Pharmaceuticals, Inc. has a beta of 0.172, suggesting its less volatile than the S&P 500 by 82.759%.

Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ironwood Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ironwood Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are smaller than Ironwood Pharmaceuticals, Inc. quarterly revenues of $122.1M. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is lower than Ironwood Pharmaceuticals, Inc.'s net income of $40.1M. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 5.54x while Ironwood Pharmaceuticals, Inc.'s PE ratio is 29.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 2.22x versus 2.27x for Ironwood Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of -301.29%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat Nektar Therapeutics's return on equity of -327.67%.

Rigel Pharmaceuticals, Inc. has a consensus price target of $51.60, signalling upside risk potential of 51.1%. On the other hand Nektar Therapeutics has an analysts' consensus of $114.43 which suggests that it could grow by 210.86%. Given that Nektar Therapeutics has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Nektar Therapeutics is more attractive than Rigel Pharmaceuticals, Inc..

Rigel Pharmaceuticals, Inc. has a beta of 1.111, which suggesting that the stock is 11.137% more volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.341, suggesting its more volatile than the S&P 500 by 34.126%.

Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are larger than Nektar Therapeutics quarterly revenues of $11.8M. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is higher than Nektar Therapeutics's net income of -$35.5M. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 5.54x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 2.22x versus 37.96x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.